Hormone replacement therapy: Optimising the dose and route of administration

Drugs and Aging

Volumn 19, Issue 11, 2002, Pages 807-818

  Montgomery Rice, Valerie ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE; CYPROTERONE; DESOGESTREL; DROSPIRENONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETYNODIOL; GESTAGEN; GESTODENE; HORMONE; LYNESTRENOL; MEDROXYPROGESTERONE; MEGESTROL; NORETHISTERONE ACETATE; NORGESTIMATE; TRIMEGESTONE;

BLEEDING; DRUG EFFECT; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED STATES; UTERUS; VASOMOTOR DISORDER;

EID: 0036448505     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219110-00001     Document Type: Review

References (71)

1. Speroff L, Whitcomb RW, Kempfert N J, et al. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996 Oct; 88 (4 Pt 1): 587-92
2. Studd J, Pornel B, Marton I, et al., for the Aerodiol Study Group. Efficacy and acceptability of intranasal 17β-oestradiol for menopausal symptoms: Randomised dose-response study. Lancet 1999 May 8; 353: 1574-8
3. Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause 1999; 6 (3): 273-6
4. Moore RA. Livial: A review of clinical studies. Br J Obstet Gynaecol 1999; 106 Suppl. 19: 1-21
5. Rannevik G, Jeppsson S, Johnell O, et al. A longitudinal study of the perimenopausal transition: Altered profiles of steroid and pituitary hormones, SHBG, and bone mineral density. Maturitas 1995 Feb; 21: 103-13
6. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000 Sep; 96 (3): 351-8
7. Notelovitz M, Lenihan Jr JP, McDermott M, et al. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000; 95 (5): 726-31
8. Stevens RE, Hanford K, Wason S, et al. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women. Int J Fertil Womens Med 2000; 45 (4): 264-72
9. Greendale GA, Reboussin BA, Hogan P, et al., for the Post-menopausal Estrogen/Progestin Interventions Trial Investigators. Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions trial. Obstet Gynecol 1998 Dec; 92 (6): 982-8
10. Iversen OE, Eid AB, Johannesen KH, et al. Transdermal estrogen treatment. A placebo controlled study [in Norwegian]. Tidsskr Nor Laegeforen 1991 Aug 30; 111 (20): 2544-6
11. Wiklund I, Berg G, Hammar M, et al. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 1992; 14 (3): 225-36
12. Ella D, Tamborini A, Leocmach Y, et al. Efficacy and tolerability of a low-dose of Oesclim® (25 mcg daily) in the management of symptomatic menopausal women: A French open-label study. Curr Med Res Opin 2000; 16 (2): 94-106
13. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy - A placebo-controlled study. Int J Fertil 1995; 40 (2): 73-8
14. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001 Jun; 75 (6): 1080-7
15. Reginster J-Y, Bruyere O, Audran M, et al. Do estrogens effectively prevent osteoporosis-related fractures? Calfic Tissue Int 2000; 67: 191-4
16. Dören M, Samsioe G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: Update on clinical trials since 1995. Hum Reprod Update 2000; 6 (5): 419-26
17. O'Connell D, Robertson J, Henry D, et al. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects. Climacteric 1998; 1: 112-23
18. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 2001 Jun 13; 285 (22): 2891-7
19. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen and progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13
20. Altman DG. A meta-analysis of hormone replacement therapy for fracture prevention [letter]. JAMA 2001 Nov 7; 286 (17): 2096-7
21. Cauley JA, Zmuda JM, Ensmd KE, et al., for the Study of Osteoporotic Fractures Research Group. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001; 86: 5700-5
22. Villareal DT, Binder EF, Williams DB, et al. Bone mineral density response to estrogen replacement in frail women: A randomized controlled trial. JAMA 2001 Aug 15: 286; 815-20
23. Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001 Oct; 86: 4717-26
24. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol Jun 1984; 63 (6): 759-63
25. Recker RR, Davies KM, Dowd RM, et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial. Ann Intern Med 1999 Jun 1; 130: 897-904
26. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol. Obstet Gynecol 1997; 177 (1): 115-9
27. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997 Dec 8; 157 (22): 2609-15
28. Speroff L, Rowan J, Symons J, et al., for the CHART Study Group. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy. (CHART study). JAMA 1996 Nov 6; 276 (17): 1397-403
29. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002 May 22/29; 287 (20): 2668-76
30. Genant HK, Cann CE, Ettinger B, et al. Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 1982 Nov; 97 (5): 699-705
31. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987 Jan; 106 (1): 40-5
32. Harris ST, Genant HK, Baylink DJ, et al. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch Intern Med 1991 Oct; 151 (10): 1980-4
33. Ettinger B, Genant HK, Steiger P, et al. Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992 Feb; 166 (2): 479-88
34. Webber CE, Blake JM, Chambers LF, et al. Effects of 2 years of hormone replacement upon bone mass, serum lipids, and lipoproteins. Maturitas 1994 May; 19 (1): 13-23
35. Mizunuma H, Okano H, Soda M, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study. Maturitas 1997 May; 27 (1): 69-76
36. American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas (TX): American Heart Association, 1999: 1-29
37. Wagner JD. Rationale for hormone replacement therapy in atherosclerosis prevention. J Reprod Med. 2000; 45 Suppl. 3: 245-58
38. Clarkson TB, Anthony MS. Effects on the cardiovascular system: Basic aspects. In: Lindsay R, Dempster DW, Jordan VC, editors. Estrogens and Antiestrogens. Philadelphia: Lippincott-Raven, 1997: 89-119
39. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens in heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208
40. Lobo RA, Zacur HZ, Caubel P, et al. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17β-estradiol on lipid and lipoprotein profiles. Am J Obstet Gynecol 2000; 182: 41-9
41. Ylikorkala O, Lim P, Caubel P. Effects on serum lipid profiles of continuous 17β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000; 22: 622-36
42. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9
43. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-33
44. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002; 288: 366-8
45. Shlipak M, Angeja BG, Go AS, et al., for the National Registry of Myocardial Infarction-3 Investigators. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001 Nov; 104: 2300-4
46. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health study. Ann Intern Med 2001 Jul; 135: 1-8
47. Schlegel W, Petersdorf LI, Junker R, et al. The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women. Clin Endocrinol 1999; 51: 643-51
48. Lobo RA, Bush T, Carr BR, et al. Effects of lower doses of conjugate equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001 July; 76 (1): 13-24
49. Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab. 2001 Jun; 86 (6): 2757-62
50. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000. Fertil Steril 2001 May; 75 (5): 898-915
51. Ettinger B, Pressman A, Bradley C. Comparison of continuation of postmenopausal hormone replacement therapy: Transdermal versus oral estrogen. Menopause 1998 Fall; 5 (3): 152-6
52. Fahraeus L, Larsson-Cohn U, Wallentin L. Lipoproteins during oral and cutaneous administration of oestradiol-17 beta to menopausal women. Acta Endocrinol (Copenh) 1982 Dec; 101 (4): 597-602
53. Jensen J, Riis BH, Strom V, et al. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987 Jan; 156 (1): 66-71
54. Lobo RA. Treatment of the postmenopausal woman. Where we are today. In: Lobo RA, editor. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. New York (NY): Raven, 1994: 427-32
55. Lethaby A, Farquhar C, Sarkis A, et al. Hormone replacement therapy in postmenopausal women: Endometrial hyperplasia and irregular bleeding (Cochrane Review). In: The Cochrane Library, Issue 4, 2001. Oxford: Update Software
56. Corson SL, Richart RM, Caubel P, et al. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17β-estradiol and norgestimate on endometrial histology. Int J Fertil 1999; 44 (6): 279-85
57. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996 Feb 7; 275 (5): 370-5
58. Archer DF, Dorin MH, Heine W, et al., for the Endometrium Study Group. Uterine bleeding in post menopausal women on continuous therapy with estradiol and norethindrone acetate. Obstet Gynecol 1999; 94 (3): 323-9
59. Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil 1999; 44 (6): 286-96
60. Ettinger B, Pressman A, Van Gessel A. Low-dosage esterified estrogens opposed by progestin at 6-month intervals. Obstet Gynecol 2001 Aug; 98: 205-11
61. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 1987; 69 (6): 929-32
62. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990; 10 (6): 1051-7
63. Tonstad S, Ose L, Gorbitz C, et al. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. J Intern Med 1995; 238: 39-47
64. Phillips A, Demarest K, Hahn DW, et al. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990; 41: 399-410
65. Archer DF, Pickar JH. Hormone replacement therapy: Effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol 2000: 96; 899-905
66. Archer DA, Pickar JH, Bottiglioni F, Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994; 83: 686-92
67. Pickar JH, Yeh I-T, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001 Jul; 76 (1): 25-31
68. Al-Azzawi F, Wahab M, Thompson J, et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: A comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 2001; 4: 343-54
69. Archer DA, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001 Jun; 75 (6): 1080-7
70. Notelovitz M, Varner RE, Rebar RW, et al. Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens. Menopause 1997; 4: 80-8
71. Trabal JF, Lenihan Jr JP, Melchione TE, et al. Low-dose unopposed estrogens: Preliminary findings on the frequency and duration of vaginal bleeding in postmenopausal women receiving esterified estrogens over a two-year period. Menopause 1997; 4: 130-8